



(51) International Patent Classification:  
**C07D 295/155** (2006.01) **A61P 35/00** (2006.01)  
**A61K 31/5377** (2006.01)

(21) International Application Number:  
PCT/US2010/048949

(22) International Filing Date:  
15 September 2010 (15.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/244,051 20 September 2009 (20.09.2009) US

(71) Applicant (for all designated States except US): **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHANG, Geoff, G.Z** [US/US]; 1372 N. Maidstone Drive, Vernon Hills, IL 60061 (US). **BRACKEMEYER, Paul, J.** [US/US]; 1717 West Catalpa Lane, Mount Prospect, IL 60056 (US). **CATRON, Nathaniel, D.** [US/US]; 305 Lakeside Drive, Vernon Hills, IL 60061 (US). **BORCHARDT,**

**Thomas, B.** [US/US]; 2433 55th Avenue, Kenosha, WI 53144 (US).



(74) Agents: **MANZARI, Oona A.** et al.; Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: **ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES**



(57) Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

**WO 2011/034934 A1**



---

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**  
GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*